FDA’s Sedation Product Workshop Will Be A Solo Affair
This article was originally published in The Pink Sheet Daily
The agency had previously solicited proposals that an outside body or bodies evaluate the issues and sponsor a conference, but has now decided to do the work for the May 3 event in-house, albeit with outside input.
You may also be interested in...
No organization acting by itself can hope to study the neurological risks of anesthesia in infants and young children, the agency says.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.